Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11599116 | 1.00 | GBA1 (0.48) | GBA1PPARGTSHRTP53CYP3A4 | |
| SCHEMBL11787564 | 1.00 | GBA1 (0.48) | GBA1PPARGTSHRTP53CYP3A4 | |
| SCHEMBL7165503 | 0.86 | GBA1 (0.47) | GBA1PPARGTSHRTP53CYP3A4 | |
| SCHEMBL15188961 | 0.78 | GBA1 (0.40) | GBA1PPARGTSHRALDH1A1TDP1 | |
| SCHEMBL10334445 | 0.71 | — | — | |
| SCHEMBL6524160 | 0.70 | GBA1 (0.47) | GBA1TSHRTP53CYP3A4MAPK1 | |
| SCHEMBL6517051 | 0.68 | GBA1 (0.50) | GBA1TSHRMAPK1ALDH1A1LMNA | |
| SCHEMBL6519035 | 0.68 | GBA1 (0.50) | GBA1TSHRMAPK1ALDH1A1LMNA | |
| SCHEMBL6519598 | 0.68 | GBA1 (0.50) | GBA1TSHRMAPK1ALDH1A1LMNA | |
| SCHEMBL6520331 | 0.68 | GBA1 (0.50) | GBA1TSHRMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581479-A1 | PROCESS FOR THE SYNTHESIS OF 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN[B]FURAN-2-ONE | Pharmacia & Upjohn Company LLC (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040147775-A1 | Process for the synthesis of 3.3A.6.6A-tetrahydro-2H-cyclopentan[b]furan-2-one | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
| WO-2004056749-A1 | PROCESS FOR THE SYNTHESIS OF 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN ‘B ! FURAN-2-ONE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1581479-A1 | PROCESS FOR THE SYNTHESIS OF 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN[B]FURAN-2-ONE | Pharmacia & Upjohn Company LLC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040147775-A1 | Process for the synthesis of 3.3A.6.6A-tetrahydro-2H-cyclopentan[b]furan-2-one | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004056749-A1 | PROCESS FOR THE SYNTHESIS OF 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN ‘B ! FURAN-2-ONE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | disclosed |
| US-4008125-A | New cyclopentene-diols and new acyl esters thereof and process for their preparation | TEIJIN LIMITED (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147775-A1 | Process for the synthesis of 3.3A.6.6A-tetrahydro-2H-cyclopentan[b]furan-2-one | CYP1B1, CYP4F3, CYP4B1 | GBA1 2383/4885PPARG 4416/4885TSHR 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.